 |
| Courtesy of Boston Scientific |
Boston Scientific's ($BSX) Watchman atrial fibrillation device improved patient quality of life over drug therapy, according to early results from its pivotal trial. The device, designed to prevent strokes in a-fib patients, bested warfarin in patient questionnaires, posting higher numbers in physical quality of life and mental health in the PROTECT AF study. Boston Scientific is in the midst of gathering data to support a PMA application with the FDA, and Watchman is already CE marked overseas to treat atrial fibrillation and protect against strokes. News